Research Areas

By stabilizing G-quadruplex DNA, a revived anticancer drug offers a new way to shut down a key oncogene.

Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity.

Gene therapies dominated the news this week, with positive results for both a CRISPR and non-viral therapy, and a U-turn decision from the FDA.

As a new wave of chronic cough therapeutics enters clinical development, researchers are questioning whether the tools used to measure treatment effects are up to the task.

Explore how confocal live-cell imaging can reveal immune-tumor interactions and cytotoxic responses in three-dimensional tumor spheroid models.

From fleet-level monitoring to faster quantitative workflows, new expectations are emerging for how mass spectrometry platforms support decision-making at scale.

The novel platform, called single-cell spatial pharmacobiology, revealed new insights into drug delivery of an antibody in Phase 1 trials.

The field's foundational biology is no longer the limiting factor. What comes next depends on whether the industry can build the manufacturing, commercial, and clinical infrastructure to match what the science already knows how to do.

Two year trial results position Gazyva as a potential first approved therapy for an autoimmune kidney disease with longstanding unmet need.

Researchers are uncovering how hidden sources of variability throughout the experimental workflow can shape scientific outcomes.